Dear TPI,
The Immunogenicity Database Collaborative (IDC) is an industry wide working group focused on creating a shared database cataloging data associated with the immunogenicity of biotherapeutics. Our first contribution is a dataset focused on clinical readouts of immunogenicity and associated relevant features (such as therapeutics characteristics, sequences, patient populations, comedications, etc.). It will be made publicly available in the next few months (just waiting on approval to publish the companion manuscript from associated organizations).
Next the IDC is looking to expand upon its V1 of the database. To do so, we are recruiting for individuals interested in contributing to/participating in the following subgroups:
-
Preclinical Subgroup --> building architecture for preclinical data, sourcing and building out a preclinical datasets (DC migration, MAPPs, T cell antigenicity, etc.) and incorporating them into the database
-
Computational Subgroup --> collaborating to automate clinical data capture from clinicaltrials.gov and EU clinical registry to expand the breadth of the current clinical dataset. A focus for this could be guided by expansion into other modalities (peptides, bispecifics, etc.) or clinical contexts of interest (biosimilars, various co-medications, etc.)
-
Clinical Subgroup --> sourcing additional clinical data points (like impacts on PK/PD, efficacy and safety). Championing for release of data on failed molecules
With your help we can advance the field and provide meaningful shared resources to improve the safety and efficacy of everyone's therapeutics. If you are interested in joining a subgroup please reply here or send an email to Vibha Jawa ([email protected]) or myself ([email protected]).
Thanks,
Dan
------------------------------
Daniel Leventhal
Director
Xaira Therapeutics
Brisbane CA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------